Namodenoson
- Generic Name
- Namodenoson
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18ClIN6O4
- CAS Number
- 163042-96-4
- Unique Ingredient Identifier
- Z07JR07J6C
- Background
Namodenoson has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 471
- Registration Number
- NCT05201404
- Locations
- 🇧🇦
843 University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
🇺🇸Site 881, Dallas, Texas, United States
🇧🇦842 University Clinical Centre Sarajevo, Sarajevo, Bosnia and Herzegovina
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 114
- Registration Number
- NCT04697810
- Locations
- 🇲🇩
911 IMSP Spitalul Clinic Republican "Timofei Mosneaga", Chisinau, Moldova, Republic of
🇧🇬933 Clinic of Gastroenterology, University Multiprofile Hosptial for Active Treatment, Sofia, Bulgaria
🇮🇱Hadassah Medical Center, Jerusalem, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath